Palbociclib in metastatic breast cancer: current evidence and real-life data
作者: Francesco Serra MD, Pietro Lapidari MD, Erica Quaquarini MD, Barbara Tagliaferri MD, Federico Sottotetti MD, Raffaella Palumbo MD, PhD
刊名: Drugs in Context, 2019
来源数据库: BioExcel Publishing Ltd
DOI: 10.7573/dic.212579
关键词: Metastatic breast cancerPalbociclibReal-life studies
原始语种摘要: The purpose of this review is to summarize the background and latest evidence for the use of palbociclib, an oral, first-in-class, highly selective cyclin-dependent kinase 4/6 inhibitor, in advanced breast cancer, with a focus on some of the unanswered questions about the performance of this agent in clinical practice. The available clinical data from both controlled clinical trials and real-life experiences concerning palbociclib-based combinations in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic disease, including patient-reported outcomes and subgroup analyses, have been reviewed and discussed. Palbociclib significantly improved progression-free survival and clinical benefit rates when added to letrozole in...
全文获取路径: PDF下载  BioExcel出版社 
分享到:

×
关键词翻译
关键词翻译
  • breast 胸部
  • metastatic 新陈代谢的
  • cancer 癌症
  • survival 生存
  • evidence 
  • neutropenia 中性白细胞增多
  • detrimental 损害
  • cyclin 细胞周期蛋白
  • endocrine 内分泌的
  • epidermal 上皮的